Moderna Inc (NASDAQ:MRNA) stock surged on Tuesday after the company shared the AACR 2024 annual meeting poster presentation of mRNA-4157 (V940) individualized neoantigen therapy plus Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in advanced unresectable HPV-negative head and neck carcinoma. In a Phase 1 trial, the data from 22 patients in patients with a type of head and neck cancer, the vaccine showed a positive response. mRNA-4157 + pembrolizumab was associated with preliminary positive clinical responses and disease control ...